

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/08	A1	(11) International Publication Number: WO 97/11681 (43) International Publication Date: 3 April 1997 (03.04.97)
(21) International Application Number: PCT/US96/15293 (22) International Filing Date: 25 September 1996 (25.09.96) (30) Priority Data: 08/536,750 29 September 1995 (29.09.95) US 08/588,272 18 January 1996 (18.01.96) US 08/630,205 10 April 1996 (10.04.96) US (71) Applicant: LAM PHARMACEUTICALS INC. [US/US]; P.O. Box 65262, Washington, DC 20035 (US). (71)(72) Applicant and Inventor: NATH, Gary, M. [US/US]; 6106 Goldtree Way, Bethesda, MD 20017 (US). (72) Inventors: DRIZEN, Alan; Suite 1201, 100 Canyon Avenue, Downsview, Ontario M3H 5T9 (CA). ROTHBART, Peter; 2475 St. Clements Avenue, Toronto, Ontario M4R 1H5 (CA). (74) Agent: NATH, Gary, M.; Nath & Associates, Suite 750, 1835 K Street, N.W., Washington, DC 20006-1203 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: SUSTAINED RELEASE DELIVERY SYSTEM AND LONG ACTING NARCOTIC ANALGESICS AND ANTAGONISTS (57) Abstract Sustained release compositions comprising a drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex. Long acting narcotic compositions comprising a water-soluble analgesic or antagonist drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

SUSTAINED RELEASE DELIVERY SYSTEM AND LONG ACTING NARCOTIC ANALGESICS AND ANTAGONISTSBACKGROUND OF THE INVENTION1. Field of the Invention

This invention relates to the preparation of a sustained release delivery system, and more particularly to a system using a polymer matrix containing a drug. The system is designed to administer effective levels of drugs over a sustained period of time when administered intramuscularly, epidurally or subcutaneously for the treatment of various disease states conditions. A particularly advantageous use of the system is the administration of a local anesthetic along the sheath of a nerve or muscle tissue to alleviate or ameliorate the effects of pain.

This invention ^{also} relates to the preparation of long acting analgesics, and more particularly to a water-soluble system for the intramuscular administration of a narcotic drug. The system is designed to administer effective levels of drugs over a sustained period of time when administered intramuscularly, for the treatment of pain and drug addiction.

2

2. Description of the Prior Art

20 Medications have been formulated to enable the
administration of drugs to occur over a wide variety of paths,
including instantaneous delivery by use of injectables, and
sustained, controlled and extended release delivery by use of
tablets, capsules, and particulate forms which enable release
25 of the drug to be controlled by various means, such as by
resistance of the structure's coating or composition against
diffusion of the drug therethrough. These systems have all
found wide applications for the delivery of drugs.

30 None of the known drug delivery systems, however, are
able to administer effective therapeutic amounts of a drug for
sustained periods of time, that is, longer than 24 to 48
hours. Actually, most delivery systems maintain effective
dosages for from several hours to daily doses before requiring
readministration. Such systems have not been found to be
35 effective for the long term administration of drugs that
require repetitive and continued use, except of course for
selected patch treatments. Drugs that have been repeatedly
administered for long term treatments include but are not
limited to ~~anesthetics~~ *analgesics, antagonists and* for treating pain, steroids and hormone
administration for maintenance, modification or alteration of
body chemistry, metabolism and hormone balance and regulation,
vitamin and mineral supplementation, and so forth. A delivery
system is therefore needed which would permit the
administration of therapeutically effective amounts of drugs
to enable a continued and sustained release for at least 24
hours to several days.

Morphine and drugs having similar structures, especially
opioids, have been used for pain relief, and primarily treatment

3

of nociceptive pain, namely that due to irritation or damage of pain receptors in the skin or nearby tissues. Examples of such narcotics include morphine sulfate, Dilaudid, Demerol, codeine, Taliwin and Percocet.

5 The problems associated with narcotic use are manifold, but primarily relate to their relative short duration for pain relief, namely two to five hours with intramuscular injection, and secondly, they are addictive, especially when used in large doses. Tolerance and physical dependence on both natural and
10 synthetic opioids develops rapidly; therapeutic doses taken regularly over a two or three day period can lead to some tolerance and dependence, and the user may show symptoms of withdrawal when the drug is discontinued. Furthermore, opioid drugs induce cross-tolerance and abusers may substitute one drug
15 for another.

 Currently, analgesics are used to treat various pain conditions in several ways.

 (1) intramuscular or oral administration of morphine, Dilaudid or codeine with repeated injections every two to five
20 hours;

 (2) patient controlled analgesia where the patient operates an intravenous drip with control of the amount of drug by a computer delivery procedure where small amounts are administered on demand; and

25 (3) continuous epidural pump infusions where the analgesic is administered by a computerized pump through tubing into the epidural space and wherein the dose is continuously adjusted.

 A delivery system is therefore needed which would permit the administration of therapeutically effective amounts of analgesic and antagonist drugs to enable a continued and sustained release
30 for at least 12 hours to several days.

4

SUMMARY OF THE INVENTION

10 The present invention relates to the formation of a long-
acting drug composition for use in treating acute, or chronic
15 conditions. More particularly, this invention relates to a
sterilized, purified, solubilized or suspended drug
composition, which comprises: a drug dispersed within a
polymer matrix solubilized or suspended in a polymer matrix,
with or without the presence of a preservative. The polymer
20 matrix is composed of a highly negative charged polymer
material selected from the group consisting of polysulfated
glucosoglycans, glycosaminoglycans, mucopolysaccharides and
mixtures thereof, and a nonionic polymer selected from the
group consisting of carboxymethylcellulose sodium,
25 hydroxyethyl cellulose, hydroxypropyl cellulose, and mixtures
thereof.

Another embodiment of this invention involves a method
for the treatment of a condition in animals, which comprises
injecting therapeutically effective dosages of a suspension or
30 solution of a sterilized, purified, solubilized or suspended
composition comprising a drug dispersed within a polymer
matrix which is solubilized or suspended in a liquid medium.
Preferably, one of the polymer materials has a mean average
molecular weight below about 800,000, and the other polymer is
a nonionic cellulose derivative.

35 The present invention ^{also} relates to the formation of long-
acting analgesic and antagonist composition for use in treating
acute or chronic pain conditions and aiding in treating drug

5

addiction. More particularly, this invention relates to an injectable narcotic drug solubilized in a liquid polymer matrix, with or without the presence of a preservative. The polymer matrix is composed of a negatively charged polymer material selected from the group consisting of polysulfated glucosoglycans, glycosaminoglycans, mucopolysaccharides and mixtures thereof, and a nonionic polymer selected from the group consisting of carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose, and mixtures thereof.

Another embodiment of this invention involves a method for the treatment of a condition in animals, which comprises intramuscularly injecting therapeutically effective doses (which may be less than the normal therapeutic dosage) of a solution of a narcotic solubilized drug within an aqueous liquid containing a polymer matrix. Preferably one of the polymer materials has a mean average molecular weight below about 800,000, and the other polymer is a nonionic cellulose derivative.

An alternate embodiment relates to the use of the present formulations to treat drug addiction.

6

DETAILED DESCRIPTION OF THE INVENTION

5 The present invention relates to the formation of a delivery system for administering a drug for a sustained period, and particularly to a polymer matrix useful for its treatment of acute, or chronic intractable pain and to the use therefor. The process involves the production and use of specialized compounds manufactured by using polymers of molecular weights below about 800,000 in a unique process for
10 the creation of specially modified molecules to treat a variety of conditions. Specifically, the invention addresses a process for manufacturing a polymer matrix suspended or solubilized in water with various drugs. The polymers must be sterilizable and acceptable for animal, and human use. In
15 this way, a suitable polymer system is formed as a matrix which is able to disperse a much lower molecular weight drug to form a solution or suspension of the active for subsequent use.

20 It has been found in conventional drug treatments that once a therapeutic dosage is used, the beneficial effect of such dosage routine wears off within several hours of its initial application, thus requiring repetitive treatment. This mechanism is common in all animal systems and involves biochemical pathways that have not yet been fully discovered
25 or identified. One possibility for this action would involve the animals own immunoglobulin system which may be responsible for identifying the presence of the chemical entity and systematically destroying it. Another may be the inherent instability of the chemical entity after its administration
30 into the animal.

35 It has been unexpectedly discovered that an effective therapeutic level of a drug may be administered once over at least a 24 hour to several day interval when the drug is suspended or entrapped in a specially designed polymer matrix containing almost equal molar ratios of a negatively charged polymer and a nonionic polymer suspended or dissolved in

and preferably over at least
a 12 to 24 hour period

7

water.

5 This system is believed to form a matrix which microencapsulates, suspends and/or entraps the active drug entity such that when it is administered it is slowly released into the systemic circulatory system or muscular tissue providing a sustained and prolonged drug release rate.

10 The molar ratio of the polymers present in the matrix is critical in this invention. It has been found that molar ratios of the negatively charged polymer to the nonionic polymer must be from 1:0.5 to 2 and preferably from 1:0.8 to 1.5 and most preferably from 1:1 to ~~1.4~~^{1.3}. At ratios either higher or lower than these levels the resulting systems tend to sheer when being prepared and form unacceptable air pockets and bubbles. Furthermore, the solutions tend to separate and form distinct polymer layers.

15 At least one of the polymers used to form the matrix of this invention must be sufficiently negatively charged to aid in the dispersion, encapsulation or solubilization of the drug. Particularly preferred polymers have mean average molecular weights below about 800,000 and preferably molecular weights between about 500,000 to 800,000 have been found acceptable to form useable polymer matrixes. Polymers with mean average molecular weights between about 700,000 and 775,000 are most preferred. Polymers having molecular weights above about 800,000 form solid gels in solution and are unable to serve in an injectable system. Furthermore, the polymers must be sterilizable and be stable during
20
25
30 sterilization so that the polymer does not lose molecular weight once formulated into the final injectable form.

Exemplary, non-limiting examples of compounds that may be used as a source of this molecular weight polymer include polysulfated glucosoglycans, glucosaminoglycans, and mucopolysaccharides, derivatives thereof and mixtures thereof.
35 Particularly preferred mucopolysaccharides are chondroitin sulfate and hyaluronic acid salts with sodium hyaluronate

8

being most preferred.

5 Hyaluronic acid (HA) occurs naturally in joint synovial fluid, where it plays a lubricating role, and may have biological activity as well. HA is a mucopolysaccharide, and may alternatively be referred to as a glycosaminoglycan. The repeating unit of the hyaluronic acid molecule is a disaccharide consisting of D-glucuronic acid and N-acetyl-D-glucosamine. Because hyaluronic acid possesses a negative charge at neutral pH, it is soluble in water, where it forms highly viscous solutions. The D-glucuronic acid unit and N-acetyl-D-glucosamine unit are bonded through a glycosidic, beta (1-3) linkage, while each disaccharide unit is bonded to the next disaccharide unit through a beta (1-5) linkage. The (beta 1-4) linkages may be broken through hydrolysis with the enzyme hyaluronidase.

15 A variety of substances, commonly referred to as hyaluronic acid, have been isolated by numerous methods from various tissue sources including umbilical cords, skin, vitreous humour, synovial fluid, tumors, haemolytic streptococci pigskin, rooster combs, and the walls of veins and arteries. It is also being synthesized artificially and by recombinant technology.

25 Conventional methods for obtaining hyaluronic acid results with a product having differing properties and a wide range of viscosities. U.S. Patent No. 2,585,546 to Hadian, discloses an example of a method for obtaining hyaluronic acid and which involves extracting acetone-washed umbilical cords with a dilute salt solution, acidifying the resulting extract, removing the clot so formed, precipitating some hyaluronic acid with protein from the acidified extract with ammonium sulfate, agitating the liquid with pyridine, precipitating another fraction highly contaminated with protein, followed by more ammonium sulfate which forces some pyridine out of solution along with the high viscosity hyaluronic acid. The hyaluronic acid collects at the interface between the two liquid phases and may be separated by filtration, centrifugation or other usual procedure. A modification of

9

this process involves the fractionation of the acidic salt extract from umbilical cords with alcohol and ammonium sulfate. Alcohol is added to the acidic salt extract, and the resulting precipitate is removed. Solid ammonium sulfate is added to the liquid until saturation and the solution forms two phases with a precipitate of hyaluronic acid at the interface.

U.S. Patent No. 4,517,296 to Bracke et al, is directed to the preparation of hyaluronic acid in high yield from streptococcus bacteria by fermenting the bacteria under anaerobic conditions in a CO₂ enriched growth medium, separating the bacteria from the resulting broth and isolating the hyaluronic acid from the remaining constituents of the broth. Separation of the microorganisms from the hyaluronic acid is facilitated by killing the bacteria with trichloroacetic acid. After removal of the bacteria cells and concentration of the higher molecular weight fermentation products, the hyaluronic acid is isolated and purified by precipitation, resuspension and reprecipitation.

One particular fraction of hyaluronic acid (HA) that exhibits excellent matrix formation according to the present invention is hyaluronate sodium having a molecular weight of between 650,000 - 800,000, preferably 700,000 - 775,000 with a high degree of purity, 95-105% free, and preferably at least 98% pure, from contamination of related mucopolysaccharides. Furthermore, this hyaluronic acid has a sulphated ash content of less than 15% and a protein content of less than 5%. Examples of usable base salts include those safe for animal and human use, such as sodium, potassium, calcium, and magnesium salts or the like.

In contrast to HA, chondroitins are mucopolysaccharides comprising repeating units of D-glucuronic acid and N-acetyl-D-galactosamine. Chondroitin sulphates are important components of cartilage and bone and are excellent for preparing the polymer matrix herein.

The negative charged polymers are generally present in the system in amounts which enable a solution or solid gel to

10

be formed. Generally, solutions are formed using amounts of about ~~0~~^{0.1} to 2.0% by weight with amounts of about 1 to about 1.5% by weight being preferred for use as an injectable. Topical gel forms may be prepared with amounts of about 2.0% to about 3.0% by weight. A particularly preferred sodium HA concentration as an injectable is ~~about 1.2% to about 1.4%~~ ^{about 1.2% to about 1.4%} by weight of the system and preferably 1.3%.

In addition to the negatively charged polymers, the polymer matrix must contain a nonionic polymer which aids in retarding the rate of absorption of the active drug and delays or slows down an animals natural absorption of the negatively charged polymer. Without the presence of this component, the drug would be rapidly absorbed, and sustained action of the active could not be achieved. Particularly preferred nonionic polymers are cellulose derivatives and particularly those selected from the group consisting of carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose and mixtures thereof. These particular polymers have been found to possess exceptional ability to form sustained release matrix formulations when used in combination with a negatively charged polymer. Such polymers are generally employed in amounts of about 0.1% to about ~~1.0%~~^{1.5%} and preferably about 0.5 to about ~~1.0%~~^{1.4%}. Amounts above about 1.0% ^{or 1.4%} result in the formation of a solid gel product when used with the negatively charged polymer. Amounts below about 0.1% have not been found suitable to prepare a storage stable solution or form a product that has sustained drug release.

A particularly preferred HEC concentration is about 1.2% to about 1.3% by weight of the system.

11

A wide variety of medicaments which are administered may be used in the delivery system according to this invention. These include drugs from all major categories, and without limitation, for example, anesthetics including those used in caudal, epidural, inhalation, injectable, retrobulbar, and spinal applications, such as bupivacaine and lidocaine; analgesics, such as acetaminophen, ibuprofen, fluriprofen, ketoprofen, voltaren (U.S. Patent No. 3,652,762), phenacetin and salicylamide; anti-inflammatories selected from the group consisting of naproxen and indomethacin; antihistamines, such as chlorpheniramine maleate, phenindamine tartrate, pyrilamine

12

maleate, doxylamine succinate, phenyltoloxamine citrate, diphenhydramine hydrochloride, promethazine, brompheniramine maleate, dexbrompheniramine maleate, clemastine fumarate and triprolidine; antitussive selected from the group consisting of dextromethorphan hydrobromide and guaifenesin; expectorants such as guaifenesin; decongestants, such as phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, ephedrine; antibiotics including amebicides, broad and medium spectrum, fungal medications, monobactams and viral agents and specifically including such as erythromycin, penicillin and cephalosporins and their derivatives; bronchodilators such as theophylline, albuterol and terbutaline; cardiovascular preparations such as diltiazem, propranolol, nifedepine and clonidine including alpha adrenoceptor agonist, alpha receptor blocking agent, alpha and beta receptor blocking agent, antiotensin converting enzyme inhibitors, beta blocking agents, calcium channel blocker, and cardiac glycosides; central nervous system drugs such as thioridazine, diazepam, meclizine, ergoloid mesylates, chlorpromazine, carbidopa and levodopa; metal salts such as potassium chloride and lithium carbonate; minerals selected from the group consisting of iron, chromium, molybdenum and potassium; immunomodulators; immunosuppressives; thyroid preparations such as synthetic thyroid hormone, and thyroxine sodium; steroids and hormones including ACTH, anabolics, androgen and estrogen combinations, androgens, corticoids and analgesics, estrogens, glucocorticoid, gonadotropin, gonadotropin releasing, human growth hormone, hypocalcemic, menotropins, parathyroid, progesterone, progestogen, progestogen and estrogen combinations, somatostatin-like compounds, urofollitropin, vasopressin, and others; and vitamins selected from water-soluble vitamins such as B complex, vitamin C, vitamin B12 and folic acid and veterinary formulations.

Particularly preferred dosage forms involve use of bupivacaine, lidocaine, vitamin B12, methyl prednisolone and adenosine-5-monophosphate sodium.

13

A wide variety of analgesics and antagonist drugs which are administered by injection may be used in the delivery system according to the invention.

One particular criteria of the drug is that they must be solubilized in the polymer matrix solution in order to be injected intramuscularly. Without limitation, this includes analgesics and antagonists that are relatively water-soluble, that is, soluble enough to be dissolved or suspended in the polymer matrix solution so that they may be administered by injection. Particularly preferred drugs include, without limitation, analgesics such as morphine and its salts, such as morphine sulfate, codeine, meperidine, methadone, propoxyphene, levoprophanol, hydromorphone, oxymorphone, oxycodone, as well as opioid antagonists and agonist-antagonists such as naloxone, naltrexone, pentazocaine, butorphanol, nalbuphine, and buprenorphine. The equianalgesic doses of exemplary opioid analgesics for severe pain is set forth in TABLE I derived from the 16th Edition of the Merck Manual, page 1414. Besides these drugs, exemplary nonlimiting drugs also include:

TALWIN® (pentazocaine lactate) which chemically is 1,2,3,4,5,6-hexahydro-6, 11-dimethyl-3-(3-methyl-3-butenyl)-2,6-methano-3-benzazocin-8-ol lactate.

DEMEROL® (meperidine hydrochloride) which chemically is 1-methyl-4-phenylisopropylate hydrochloride.

Methadone Hydrochloride which chemically is 3-heptanone, 6-(dimethylamino)-4,4-diphenyl-, hydrochloride.

LEVO-DROMORAN® also known as levorphanol tartrate.

BUPROENEX® (buprenorphine hydrochloride) which chemically is 17-(cyclopropylmethyl)- α -(1,1-dimethylethyl)-4,5-epoxy-18, 19-dihydro-3-hydroxy-6-methoxy- α -methyl-6, 14-ethenomorphinan-7-methanol, hydrochloride [5 α ,7 α (S)].

MSIR® (morphine sulfate) which chemically is 7,8

14

didehydro-4,5- α -epoxy-17-methyl-morphinian-3,6 α -diol sulfate (2:1) (salt) pentahydrate.

- 5 DILAUDID® also known as hydromorphone hydrochloride.
SUFENTA® (sufentanil citrate) which chemically is N-[-4-(methoxymethyl)-(-1-[2-(2-thienyl) ethyl]-4-piperidinyl]-N-phenylpropanamide 2-hydroxy -1,2,3,-propanetricarboxylate.
- 10 SUBLIMAZE® (fentanyl citrate) which chemically is N-(1-phenethyl-4-piperidyl) propionanilide citrate.
AFENTA® (afentanil hydrochloride) which chemically is N-[1-[2-(4-ethyl -4,5-dihydro-5-oxo-1H-tetranol-1-yl) ethyl]-4- (methoxymethyl)-4-piperidinyl]-N-phenyl propanamide monohydrochloride.
- 15 PERCOCET® which is a combination of oxycodone hydrochloride and acetaminophen.
NUMORPHAN® (oxymorphone hydrochloride) which chemically is 4,5 α -Epoxy-3,14-dihydrox-17-methylmorphinon-6-one hydrochloride.

The solutions or suspensions of the present invention may be prepared in a variety of ways. For example, the polymers may be dissolved in water and purified either separately or jointly and then the active drug added to the system.

A particularly preferred procedure involves separately dissolving the nonionic polymer in water and centrifuging the material to form a solution and remove impurities. This may be conveniently done at rotation speeds of 2000 rpm for times of about 30 minutes to about two hours.

15

In contrast, the charged polymer may be blended and stirred in water until it is dissolved. This process must be done while avoiding the formation of bubbles and while freeing the polymer of its electrostatic activity. Furthermore, the molecular weight of the polymer must not be significantly changed during processing and as such mild process conditions are required. Processing conditions of 400 - 600 rpm for durations of 16 - 24 hours have been found acceptable to produce stable solutions or gels of the charged polymer.

Conventional pharmaceutically acceptable emulsifiers, suspending agents, antioxidants (such as sodium meta-bisulfate) and preservatives may then be added to this system. Once all the components are blended together, such as by mixing 400 - 600 rpm for one to four hours, the system is filled into tubes and sterilized. The resulting system is a clear solution which is storage stable for several years.

The drug may then be added to the homogenous solution or separately dissolved or disbursed in water. Emulsifiers, suspending agents and preservatives may then be added to this system. Once all the components are blended together, 400 - 600 rpm for 1 to 4 hours, the system is filled into tubes and sterilized. The resulting system is a clear solution which is storage stable for several years.

When gels are prepared, the resulting system is also a clear gel or opaque which can be filled into tubes or containers and stored for future use. The formulations may be used topically and also contain conventional pharmaceutically acceptable excipients well known to those skilled in the art, such as surfactants, suspending agents, emulsifiers osmotic enhancers, extenders and dilutants, pH modifiers as well as fragrances, colors, flavors and other additives.

16

As indicated above, the drugs may be blended with the aqueous polymer matrix at the time of manufacture or simply mixed together, such as by shaking, at the time of use. As such, the drug when in the form of a water-soluble solid is simply diluted with sterilized water or polymer matrix solution, dissolved and immediately injected into the patient. Alternatively, previously prepared solutions of the drug are blended with the polymer matrix solution, such as in a syringe or the cartridges already containing the solutions, and then injected into the patient. These procedures enable the use of commercially prepared narcotic dosage forms without need for separate processing, handling or storage procedures.

The present long acting narcotic delivery system enables the use of reduced levels of narcotics to be administered over a given period of time which does not cause the highs and lows associated with the two to five hour doses. It also is very likely to decrease the potential for drug addiction by reducing the level of doses required to reduce the pain. In this regard, it has been found that use of a single or multiple amount of a single dose (of a conventional dosage) administered once every 24 hours when mixed with the aqueous polymer matrix will achieve the same effect as six to ten conventional doses administered every two to five hours of duration.

The injection of a single daily dose is extremely easy and safe to administer and obviates the need for machinery maintenance (pump devices), continuous nursing care monitoring and dosage recalculation associated with epidural pumps.

The dosage system can be formed with or without the use of pharmaceutically acceptable preservatives. A significant advantage of the dosage form of the present system relates to its ability to allow the drug to slowly diffuse through tissue when injected intramuscularly, thus allowing for an effective therapeutic dose to be present for many hours.

17

In this regard, it should be noted that reference to therapeutically effective dose does not necessarily relate to conventional dosage levels, but does relate to drug levels that achieve an effective therapeutic level at the dose employed, which may be the same level but not at the same frequency of administration. This thus not only significantly reduces the number of doses required to achieve the same effect, it reduces costs, maintenance and health hazards associated with conventional treatment therapies. Additionally, it results in immediate and continued drug release for long periods of time spanning at least 18 hours to even days.

Doses may vary from patient to patient depending on the type and severity of the condition being treated and the drug being administered. Generally, doses of 1 ml to 10 ml may be administered with preferred doses using 4 ml of matrix solution.

The formulations of this invention may be used to treat a variety of animal conditions and physical states. These systems have particular application to pain management, namely the treatment and alleviation of pain associated with any disease, condition or physical state.

Without being limited to the specific pain being treated, the preparations of this invention may treat the following nonlimiting locations or sources of pain: abdominal, such as in appendicitis, dysmenorrhea, musculoskeletal, pelvic, peptic ulcer, psychogenic, and urologic; acute; arm; backache; cancer; cardiac (myocardial ischemia); chest; dental; ear; esophageal; eye; face; head; and neck; in fibromyalgia; foot; and leg; heel;

ischemic pain such as in myocardial, peripheral arterial, low back, in mitral valve prolapse, in myocardial infarction, myofascial pain syndrome (fibromyalgia, fibromyositis), neck, neuropathic, neurotransmitter abnormality, nociceptive, and nocturnal pain; pelvic; pericardial; in peripheral arterial disease; phantom limb; pleuritic; polyneuropathy; postmastectomy syndrome; postoperative; psychogenic; in pulmonary embolism; in renal disease, such as colic; root avulsions; shoulder; stump; thalamic; in goes; and toothache.

18

With regard to uses

after surgery, the complex may be used following abdominal, cervical, thoracic or cardiac surgery, whereby multiple layers of tissue, as being sewed back together, are treated with the system. Such treatments aid in a patient's recovery by not only avoiding addictive drug use such as a morphine drip, but result in the immediate and long term relief of pain to enable rapid rehabilitation.

When used epidurally, the formulations of this invention have been found to alleviate pain without the loss of motor or sensory functions. This result is completely unexpected and not known with prior epidural nerve blocks. In this way, patients who are treated epidurally experience a remission or loss of the pain during the time period being treated yet maintain substantially all motor and sensory skills and functions.

The phrase "back pain" as used herein refers to all conditions which arise from congenital or traumatic disfunction of physical structures in the back of an animal, such as a human. These include spinal, bone, nerve and muscle origin pain, and include but are not limited to disc damage caused by trauma, disease or congenital defects; degenerative conditions, arthritic disease, accidental injury, nerve impingement such as pinched nerve, inflammatory conditions, neuromuscular diseases, sports injuries and so forth.

Besides chronic and intractable pain where injections of the matrix solution may be required, the present solutions may be used to aid in surgical procedures such as in post surgical pain treatments.

19

The phrase "surgical procedure" refers to those internal and external procedures where a physician desires to block sensory effects prior to, during or after performing surgical procedures. While being virtually unlimited in scope as in the procedures which can be performed, exemplary external procedures include: cosmetic surgery, hair transplant surgery, procedures for trauma wounds, such as knife and bullet wounds, accidental lacerations, removal of skin growths such as warts, moles and benign or malignant growths, hemorrhoidal removal or other treatments requiring anesthesia. Furthermore, the inventive compositions are able to provide sustained anesthesia effects when used prior to, during or after internal surgical procedures. Again, without being limited to specific surgical procedures, exemplary procedures would involve abdominal, cervical, thoracic or cardiac surgery.

With regard to uses after surgery, the solutions may be used following abdominal, cervical, thoracic or cardiac surgery, whereby multiple layers of tissue are treated with the system, such as during or after the surgical procedure. Such treatments
5 aid in a patient's recovery by not only avoiding addictive drug use such as a morphine drip, but result in the immediate and long term relief of pain to enable rapid rehabilitation.

It has also been unexpectedly found that when the system is administered in a repetitive manner, once the effects of the
10 active drug are reduced in intensity or effectiveness, such repeat treatments may result in a synergistic effect by enhancing the initial term of relief to a period which exceeds the initial time of relief. This is also experienced on subsequent
15 treatments. In this way, the present formulations are able to extend relief or treatment from normally several hours to at least 12 to 24 hours to several days of relief. The use of repeat injections thus enhances drug release which significantly reduces drug dependence. It also results in the relief of
continued tissue damage and may even assist in tissue repair.

20 Regardless of the route of administration elected, the formulations of the present invention are formulated into pharmaceutically acceptable dosage forms by conventional methods known in the pharmaceutical art.

As discussed above, an effective but nontoxic amount of the
25 system is employed in treatment. The dose regimen for administering drugs or treating various conditions, such as pain as described above, is selected in accordance with a variety of factors including the type, age, weight, sex, and medical condition of the subject, the severity of the pain, the route of
30 administration and the particular complex or combination of drugs employed. Determination of the proper dose for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dose is increased by small
35 increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

21

Generally, amounts of drug may vary from 0.0001% to about 50% by weight of the system when using injections having 2 to 20 ml concentrations and preferably 3 to 10 ml injectable amounts.

5 Besides treatment of pain, the aqueous system of this invention may be used to treat drug addiction by aiding in the administration of reduced levels of narcotics to addicts as well as using reduced frequency of administration in detoxification and maintenance programs.

10 In this regard, it should be noted that the withdrawal syndrome from an opioid generally includes symptoms and signs opposite to the drug's pharmacologic effects (e.g., CNS hyperactivity). The severity of the withdrawal syndrome increases with the size of the opioid dose and the duration of dependence. Symptoms begin to appear as early as 4 to 6 hours
15 after withdrawal and reach a peak within 36 to 72 hours for heroin. The initial anxiety and craving for the drug are followed by other symptoms increasing in severity and intensity. A reliable early sign of abstinence is an increased resting respiratory rate, that is greater than 16/min. usually
20 accompanied by yawning, perspiration, lacrimation, and rhinorrhea. Other symptoms include mydriasis, piloerection ("gooseflesh"), tremors, muscle twitching, hot and cold flashes, aching muscles, and anorexia. The withdrawal syndrome in persons who have been taking methadone develops more slowly and overtly
25 less severe than heroin withdrawal, although users may perceive it as worse.

Currently, methadone substitution is the preferred method of opioid withdrawal. Methadone is given orally in the smallest amount that will prevent severe signs of withdrawal but not
30 necessarily all signs. Close observation of the patient is important because the patient's subjective symptoms are unreliable. Many of the symptoms of withdrawal can be mimicked by anxiety states. Generally, 20 mg/day of methadone will block the symptoms of severe withdrawal. Higher doses should be given
35 only on direct observation of the physical signs of withdrawal, since addicts are unreliable in reporting the size of their habits. Doses of 25 to 45 mg can produce unconsciousness if the

22

person has not developed tolerance for heroin or methadone. Once a suppressing dose has been established, it should be reduced progressively by not more than 20% each day. Patients commonly become emotionally upset and frequently request additional medication. Chloral hydrate 500 to 1000 mg may be given orally for several nights to improve sleep. The acute manifestations of withdrawal usually subside within 7 to 10 days, but patients often complain of weakness, insomnia, and a severe pervasive anxiety for several months. Minor metabolic and physiologic effects of withdrawal may persist for up to six months. Conventional procedures treat heroin withdrawal with oral methadone, but the usual low-grade level of dependence can be treated with propoxyphene napsylate or even benzodiazepines, which are not cross-tolerant to opioids. These difficulties would be overcome with use of the present systems.

Unlike methadone, the central α -adrenergic drug clonidine can halt essentially all signs of opioid withdrawal. This probably relates to diminution of central adrenergic outflow secondary to stimulation of central receptors (the same mechanism by which clonidine lowers BP). This theory supports the importance of central adrenergic discharge in the evolution of the opioid withdrawal syndrome. However, clonidine is not a benign drug. Besides causing hypotension and drowsiness, its withdrawal may precipitate restlessness, insomnia, irritability, tachycardia, and headache. Its overall contribution to therapy is minor. Withdrawal is not a difficult problem for patient or clinician; abstinence, which clonidine does not aid, is. The present system would overcome this difficulty.

Experiments with L-acetyl α -methadol (LAAM), a longer-acting synthetic opioid, give hope of help to some addicts and of removing the problem of expensive daily client visits or take-home medication, which ensures some diversion. The culture's loss of faith in methadone maintenance or at least the lessening commitment of public money has diminished the number of treatment facilities and the amount of research given to LAAM.

Unlike the opioids, dependence on anxiolytic and hypnotic drugs raises other difficulties.

23

Barbiturates and ethanol are strikingly similar in their syndromes of dependence, withdrawal, and chronic intoxication. When intake is reduced below a critical level, a self-limited abstinence syndrome ensues. Symptoms of withdrawal from barbiturates and other sedative-hypnotics can be suppressed completely with a barbiturate. Tolerance develops irregularly and incompletely so that considerable behavioral disturbances and psychotoxicity persist, depending on the drug's pharmacodynamic effects. Some mutual but incomplete cross-tolerance exists between alcohol and the barbiturates as well as the nonbarbiturate sedative-hypnotics, including benzodiazepines.

In susceptible patients, psychologic dependence on the drug may develop rapidly; and, after only a few weeks, attempts to discontinue it exacerbate any initial insomnia and result in restlessness, disturbing dreams, frequent awakening, and feelings of tension in the early morning. The extent of physical dependence is related to dose and the length of time that the drug has been taken; e.g., pentobarbital 200 mg/day may be ingested for many months without significant tolerance developing; 300 mg/day may induce an abstinence syndrome on terminating medication if ingested for more than three months; and 500 to 600 mg/day may provoke an abstinence syndrome after one month.

The standard procedure for treating dependence on depressants, particularly barbiturates, is to reintoxicate the patient and then withdraw the drug on a strict schedule, being alert for signs of marked withdrawal. Before beginning withdrawal, one can evaluate sedative tolerance with a test dose of pentobarbital 200 mg orally given to the nonintoxicated, fasting patient; 1 to 2 hours later this test dose produces drowsiness or sleep with response to arousal in individuals with no tolerance to pentobarbital. Patients with intermediate levels of tolerance may show some impairment, whereas patients tolerant to 900 mg or more show no signs of intoxication. If the 200-mg dose has no effect, the tolerance level can be determined by repeating the test every 3 to 4 hours with a larger dose. Severe anxiety or agitation may increase the patient's tolerance. Once

24

The following examples are illustrative of preferred embodiments of the invention and are not to be construed as limiting the invention thereto. All polymer molecular weights are mean average molecular weights. All percentages are based on the percent by weight of the final delivery system or formulation prepared unless otherwise indicated and all totals equal 100% by weight.

Example 1

This example demonstrates the formation of an anaesthetic preparation which produces long-acting anaesthesia either when injected epidurally, or intramuscularly.

MATERIALS

Bupivacaine	0.65%
Hydroxyethyl cellulose (HEC)	1.1%
Hyaluronate Sodium (HA)	1.0%
Sterile Water	Q.S.
Batch Size	1000 ml

Into a sterilized glass vessel is added 500ml of the

25

sterile water which is stirred at 400-600 rpms. Slowly add 10 grams of HA having a molecular weight or around 700,000 to 775,000 and a purity described previously.

5 Allow to stir for 10-20 hours until all the HA Polymer has dissolved into the water and a crystal clear viscous solution has formed.

10 Prepare a 1.1% solution of HEC by adding 11 grams of the solid material, under aseptic conditions to 275 ml of sterile water. Allow to dissolve for 1 to 2 hours while stirring. Add the HEC solution to the HA solution and mix for 2 to 4 hours at 400-600 rpms until a homogenous solution is produced.

15 Dissolve 6.5 grams of bupivacaine (bupivacaine) in 225ml of the sterile water and allow to mix for 1-2 hours at 200-400 rpms. Slowly add the bupivacaine solution to the HA/HEC homogenous mixture and mix for 2-4 hours at 400-600 rpms.

The resulting product is a clear solution which should be free of air bubbles.

20 Using aseptic techniques, the solution is then filled into suitable vials or ampules for use and stored.

Example 2

25 The procedure of Example 1 was repeated except that the bupivacaine was replaced with 2% lidocaine. The resulting product was a clear solution free of air bubbles.

Example 3

30 The procedure of Example 1 was repeated except that the bupivacaine was replaced with 10% adenosine-5-monophosphate sodium. The resulting product was a clear solution free of air bubbles.

Example 4

35 The procedure of Example 1 was repeated except that the bupivacaine was replaced with 20 to 80 mg/ml methyl prednesolone. The resulting product was a homogenous and miscible suspension.

26

Example 5

5 The procedure of Example 1 was repeated except that the bupivacaine was replaced with various vitamins, namely 10 milligrams B₁, 15 micrograms folic acid, 1000 micrograms Vitamin B₁₂, or 2 milligrams each of Vitamin B₂ and B₆. The resulting product was a clear solution of free air bubbles.

Example 6

10

This example demonstrates the use in vivo of the Example 1 preparation with various patients suffering from chronic pain.

15

Run A

A 51-year old man has complained of pain in the right temple (this had been present for 15 years), pain in the neck; and generalized headaches.

20

In 1979, Mr. A was struck in the right temporoparietal area by a heavy machine while at work. Afterwards he developed severe pain in the right temporoparietal area. This gradually spread to involve the whole right side of his head. The pains became more and more frequent until they became constant. In addition he has in the last few years developed ongoing neck pain and generalized headaches.

25

Physical Examination

30

Physical examination has revealed tenderness in the right temporoparietal area as well as in the right supraorbital area and also in the right occipital area. He also has tenderness of the right facet joints and less so on the left. Investigations have included:

35

1. CT scans of the brain
2. X-rays of the head
3. X-rays of the neck

27

4. Facet diagnostic blocks of the cervical spin
5. CT myelogram of the cervical spin

Patient A's diagnosis is as follows:

5

1. Damage of the peripheral nerves around the periosteum in the right temporoparietal area. (Site of injury headache)
2. Facet joint disease of the cervical spin
3. Recent cervical disc herniation

10

Patient A has undergone the following treatments that provided up to 1 day of relief:

15

1. Injections with local anesthetic and occasionally with steroids of the right supraorbital and temporoparietal area
2. Occipital blocks
3. Paravertebral blocks of the cervical facet joints

20

25

In general, the tempoproparietal blocks have provided about one day of relief.

Treatment with the Example 1 Formulation

30

Injections were carried out in the right temporal parietal area using about 8 cc of the long-acting bupivacaine formulation.

In addition one injection was made into the paracervical muscle.

35

RESULT

The patient obtained about five days of good relief in the temporal parietal area, as well in the trigger point areas.

28

SIDE-EFFECTS

The injection of this amount of bupivacaine in a conventional injectable form would have resulted in the onset of pain, inflammation and soreness at the injection site. Relief of pain would have been observed over four to eight hours before reoccurring.

RUN B

This 43-year old lady is complaining of headaches; neck aches; pain in the mid-thoracic area; low back pain; pain going down the legs; pain going down the arms. She has had these for about ten years.

Ms. B started to have pains in her low back and neck with headaches following a motor vehicle accident in 1978. Following this she was involved in six other motor vehicle accidents. Over the years and with successive accidents, her symptoms increased until she had pains as noted above. Basically she is in pain all the time with pain throughout her body.

Physical examination has shown marked spasm of the whole of the paraspinal musculature from the nuchal line down to the sacrum. The sacroiliac joints were fixed. However, reflexes of the upper and lower limbs were normal indicating that there was no real radiculopathy.

Patient has undergone the following investigations:

1. X-rays of the cervical and lumbar spines showed some degenerative changes.
2. Her recent CT Myelograms of the lumbar and cervical spines did not reveal any disc herniations.
3. Facet diagnostic blocks of the lumbar and cervical spines were equivocal as to whether there was significant facet disease causing the pain or not.

29

Patient has undergone the following unsuccessful treatments:

1. Analgesics and especially Fiorinal daily
2. Occasional muscle relaxants
3. Sedatives
- 5 4. She was turned down for a psychologically oriented rehabilitation program because it was felt that her problems were too severe and that she would not benefit.
- 10 5. Trigger point injections of the paraspinal muscles of the neck, thoracic spin and lumbar spine produced some temporary relief including some relief off the pain down the legs and arms.
6. Occipital blocks produced some temporary relief of the headaches.

15 The relief by local anesthetic blockades lasted one two days.

Treatment with the inventive formulation of Example 1:

20 In the past month the patient was tried on long-acting bupivacaine. The injections were carried out into trigger point areas of the lumbar paravertebral musculature and gluteal musculature.

RESULT

25 The patient received about five days of good relief with these trigger point injections.

SIDE-EFFECTS

30 With the long-acting Bupivacaine, it was again noted that there was less post-injection pain than the regular Bupivacaine. Furthermore there was no redness at the injection site. Furthermore, the post-injection irritability and general side-effects were less than is experienced with the use of regular Bupivacaine.

RUN C

This 49-year old lady is complaining of constant neck

30

ache; constant supraorbital pain; pain in the trapezii; mood, memory, concentration disturbances; uncontrolled weeping. She has had these since 1987.

5 Ms. C was well and active, working as an assistant school principal until 1987 when she was involved in a minor motor vehicle accident. Following this she developed the above-noted symptoms.

10 She has undergone facet diagnostic blocks which were positive and so indicated facet damage. She underwent facet joint rhizolysis which relieved the pain in her neck and supraorbital areas for about eight months, but then the pains returned. This was presumably to regeneration of the facet nerves.

15 She has been investigated by neuropsychologists because of her mood, memory and concentration and sleep disturbances. She appears to have a combination of minor head injury and post-traumatic emotional disorder. She has not been able to work for several years and this has contributed to a feeling
20 of guilt and worthlessness.

The paracervical muscles are tender and swollen and the facet joints from C2 to C6 are tender bilaterally. The supraorbital nerves are tender to 3+.

25 Patient C has undergone the following investigations:

1. Facet diagnostic blocks which were positive
2. CT myelogram which showed a disc herniation at C5-6
3. CT scan of the brain which was normal
4. SPECT scan of the brain which was normal

30

Patient C's diagnosis is as follows:

1. Facet damage of the cervical spine causing the headaches including the frontal headaches
2. Cervical disc herniation
- 35 3. Post-traumatic emotional disorder
4. Possible minor head injury

31

Patient C has undergone the following unsuccessful treatments:

1. Antidepressants
2. Hypnotics for sleep
3. Analgesics for pain
4. Comprehensive psychotherapy
5. Occipital and supraorbital nerve blocks with trigger point injections of the paracervical muscles. These have produced about two days of relief after each block.

Treatment with the inventive preparation of Example 1:

In the past month this patient was tried on long-acting Bupivacaine. The injections were carried out into the paracervical and trapezius musculature. As well as in the occipital nerves. In addition, supraorbital blocks were done.

RESULT

The patient received about four to five days of good pain relief in the paracervical musculature, this cut down a lot of the occipital pain. In addition, the supraorbital blockade with long-acting Bupivacaine provided about 4 days of relief. In the past we had used regular Bupivacaine and this provided about 12 hours to one day of relief only.

Once again it was noted that there was no swelling or redness or sense of irritability such as post-injection pain with the present long-acting Bupivacaine formulations.

32

Example 7

This example demonstrates the formation of a preparation which produces long-acting analgesia when injected intramuscularly.

MATERIALS

Dilaudid (hydromorphone hydrochloride)	15 mg
Hydroxyethyl cellulose (HEC)	1.25%
Hyaluronate Sodium (HA)	1.37%
Sterile Water	Q.S.
Batch Size	1000 ml

Into a sterilized glass vessel is added 500 ml of the sterile water which is stirred at 400-600 rpms. Slowly add 13.7 grams of HA having a molecular weight of around 700,000 to 775,000 and a purity described previously.

Allow to stir for 10-20 hours until all the HA polymer has dissolved into the water and a crystal clear viscous solution has formed.

Prepare a 1.25% solution of HEC by adding 12.5 grams of the solid material, under aseptic conditions to 275 ml of sterile water. Allow to dissolve for 1 to 2 hours while stirring. Add

33

the HEC solution to the HA solution and mix for 2 to 4 hours at 490-600 rpms until a homogenous solution is produced. Using aseptic techniques, the solution is then filled into suitable vials or ampules and heat sterilized at 120° C for 20 minutes. The vials or ampules are then ready for use or storage.

Dissolve 15 mg of Dilaudid in 225 ml of the sterile water and allow to mix for 1-2 hours at 200-400 rpms. Alternatively, commercially available solutions of Dilaudid may be used, such as Dilaudid regular containing 2 milligrams drug per milliliter ampule or Dilaudid HP containing 10 milligrams drug per milliliter ampule. Slowly add the Dilaudid solution to 4 ml of the HA/HEC homogenous solution and mix rapidly.

The resulting product is a clear solution which is free of air bubbles and ready for use.

Example 8

The procedure of Example 7 was repeated except that morphine sulfate was used instead of Dilaudid. The morphine sulfate is provided as a solution blended with the matrix solution and may contain 50 mg drug in 1 ml solution blended with 4 ml matrix as well as 100 mg drug in 1 ml solution blended with 4 ml matrix solution.

Example 9

The procedure of Example 7 was repeated except that Demerol was used instead of Dilaudid. The Demerol may be conveniently provided in 5 ml ampules containing 50 mg drug. As such doses of 150 mg may be prepared by blending three (3) 5 ml ampules blended with 4 ml of matrix solution. The resulting solution was a clear solution which was free of air bubbles and ready for use.

Example 10

This example demonstrates the in vivo use of the Example 7 preparation with various patients suffering from chronic pain.

Run A

MAIN COMPLAINT:

This 48-year-old man is complaining of right-sided cluster headaches which are continuous.

HISTORY:

Mr. T. started to develop cluster headaches about 13 years ago.

34

Initially these were on an occasional basis which became gradually more severe and also more frequent. About six years ago, they became constant, and the patient had severe constant pain which almost totally incapacitated him. He has contemplated suicide. The pain is always mainly behind the right eye. This is a severe pain rated as 10/10. It is also in the right occiput and travels like a rod all the way to behind the right eye. It is associated with tenderness of the right eye lid and lacrimation also rhinorrhea. In going over his early history, it was found that he had his first headache at age 11. This occurred when he fell over the front of the handle bars of his bicycle and landed on his chin. At that time, he developed a headache which was exactly like the clusters he has now. This went away after a few days. Following this, he was involved in two minor motor vehicle accidents, and again on each occasion he developed right-sided cluster headaches which eventually cleared up.

PHYSICAL EXAMINATION:

This reveals a thin man who is somewhat emaciated because of his loss of appetite and severe pain. The right eye lid is constantly drooping, and there is frequent lacrimation from the right eye. There is marked tenderness of the right greater occipital nerve, and less tenderness of the left greater occipital nerve. The right facet joints at C2-3, C3-4 are also tender. Facet diagnostic blocks did not relieve the frontal pain. Occipital blocks have relieved the pain going from the occiput through toward the right eye, but did not entirely relieve the pain in the right eye. The only way this has been relieved is when the right infraorbital or retro-orbital blocks have been done in addition to the occipital blocks.

TREATMENT COURSE:

He has been having weekly blocks of the greater occipital nerve and infratrochlear nerve for two years now. This provide up to 36 hours of relief. The rest of the time, he has such severe pain that he would be totally incapacitated without narcotics. For the past nine months, he has been prescribed Dilaudid 4 mg every four hours. This has to be taken with Benadryl, otherwise

35

USE OF LONG-ACTING POLYMER WITH DILAUDID:

The regular Dilaudid had to be given at least six times a day. However, when Dilaudid 20 mg was mixed with polymer solution of Example 7, about 12 to 16 hours of relief could be obtained. The quality of relief is very good, and he is able to work as a movie director as long as he has pain relief. Previously, he was incapacitated from work by the pain. As indicated, with the plain Dilaudid injection he gets about 2 hours of fairly good relief, but with the polymer solution and Dilaudid he gets 12 to 16 hours of excellent relief. During this time, he is not sleepy or uncomfortable and feels reasonably normal.

Run BMAIN COMPLAINT:

This 38-year-old woman has complained of pain in the left cervico-occipital temporal area for about ten years.

HISTORY:

In about 1979, Ms. G was abused on a continuing basis by her husband. He would hold her head and hit it against the wall and shake the head. It was at that time that she started to develop left occipitocervical temporal headaches. These were initially infrequent, but in the past ten years they have been almost continuous. She was mistakenly diagnosed as having migraine by her previous physicians.

PHYSICAL EXAMINATION:

This revealed tenderness in the left greater occipital nerve area to 4+, and tenderness of the left facet joints at C2-3 and C3-4. The right greater occipital nerve and facet joints were not especially tender.

INVESTIGATIONS:

1. X-rays of the head and neck were normal.
2. Facet diagnostic blocks at C2-3 and C3-4 on the left were negative.
3. C2 diagnostic block on the left entirely relieved her pain.
4. Greater occipital nerve blocks on the left have relieved her pain.

The diagnosis was as follows: Damage of the occipitocervical junction possibly the C1-2 facet area. This is causing a left

36

occipital neuralgia.

TREATMENT:

Occipital nerve blocks initially provided 2 to 3 days of relief, but more recently they have only provided one day of relief at a time. She has been getting occipital blocks on a weekly basis which relieved her pain for a couple of days at a time, but more recently one day at a time. In between she has been getting Percocet. However, in the last few months she could not take Percocet because of the gastrointestinal disturbance. She was then put on Dilaudid 4 mg every four hours. This made her very weak, and she could not function after it, and she found she had to take it at least every four hours and sometimes every three hours.

USE OF LONG-ACTING POLYMER WITH DILAUDID:

When 10 mg of Dilaudid was administered with the polymer solution, the pain relief was 16 to 18 hours with each injection. This produced a smooth degree of relief, and she was not nearly as tired or weak as when she took the Dilaudid without polymer solution.

Run C

MAIN COMPLAINT:

This 48-year-old nurse is complaining of severe constant headaches and neck aches. She has had these for about eight years.

HISTORY:

Ms. W. was involved in a motor vehicle accident in 1988. Following this, she was unconscious for a few moments. The next day, she started to develop severe neck aches and headaches which she had never experienced before, and these have not improved over time. Currently she has almost constant severe neck aches which radiate up the back of the head and involve the whole head. Often these are of a throbbing nature. She has had numerous nerve blocks and pain killers over the years to keep her going. Without these treatments, she would be totally incapacitated.

PHYSICAL EXAMINATION:

Examination has revealed marked limitation of movement of the

37

PHYSICAL EXAMINATION:

Examination has revealed marked limitation of movement of the neck to about 30% of normal in both flexion and extension and rotation. The neck muscles are very tender to palpation, and they are swollen. The occipital nerves are tender to 3+ bilaterally, and the face joints are exquisitely tender bilaterally from C2 to C6.

INVESTIGATIONS:

1. X-rays of the neck showed degenerative changes.
2. MRI of the neck has shown disc herniations.

TREATMENTS:

As noted, she has been receiving occipital nerve blocks with analgesics for several years, but she has required increasingly frequent nerve blocks and increasing doses of analgesics. Recently, she had been using fentanyl patches 50 μ /hr. These worked well initially, but ceased to be effective after a few weeks. She was then given Dilaudid 4 mg every four hours by intramuscular injection. She would obtain about two hours of good relief with some degree of relief in the first hour before the injection reached its peak level, and begin partial relief toward the end of the four hours. As noted, there were only two hours of good relief each time.

USE OF LONG-ACTING POLYMER WITH DILAUDID:

She was then given Dilaudid blended with polymer solution as set forth in Example 7 wherein she experienced about 18 hours of good relief. During this time, she was able to function well and could carry out her business functions entirely comfortably without any nausea or tiredness. She found the use of this drug to be very comfortable, and she was able to function normally.

38

TABLE I

EQUIANALGESIC DOSES OF OPIOID ANALGESICS FOR SEVERE PAIN*

Drug	IM (mg)	Oral (mg)
Morphine	10	60†
Oxymorphone	1	
Hydromorphone	1.5	7.5
Levorphanol	2	4
Methadone	10	20
Oxycodone	15	30
Meperidine	75	300
Codeine	130	200
Pentazocine	60	180
Nalbuphine	10	-
Butorphanol	2	-

* Equivalences are based on single-dose studies.

39

TABLE II

Drug	Doses Producing Dependence (mg/day)	Time Necessary to Produce Dependence (days)	Dosage Equivalent to 30 mg Phenobarbital (mg)
Secobarbital	500-600	30	100
Pentobarbital ("yellow jackets")	500-600	30	100
Amobarbital ("blues")	500-600	30	100
Amobarbital-secobarbital combination ("rainbows")	500-600	30	100
Gluethimide	1250-1500	60	500
Methyprylon	1200-1500	60	300
Ethchlorvynol	1500-2000	60	500
Meprobamate	2000-2400	60	400
Chlordiazepoxide	200-300	60	25
Diazepam	60-100	40	10
Methaqualone	1800-2400	30	300
Chloral hydrate	2000-2500	30	500

40

The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications are intended to be included within the scope of the following claims.

5

41

WHAT IS CLAIMED IS:

1. A sterilized, purified, long acting drug composition, which comprises:

5 an active drug dispersed within a polymer matrix which is solubilized or suspended in a liquid medium; wherein the polymer matrix is composed of negative charged polymers blended with nonionic polymers.

10 2. The composition of claim 1, wherein the highly negative charged polymer material is selected from the group consisting of polysulfated glucosoglycans, glycosamineolycans, mucopolysaccharides and mixtures thereof.

15 3. The composition of claim 2, wherein the negative charged polymer material is selected from the group consisting of hyaluronic acid salts, chondroitin sulfate and mixtures thereof.

20 4. The composition of claim 3, wherein the negative charged polymer material has a mean average molecular weight below about 800,000.

25 5. The composition of claim 3, wherein the hyaluronic acid salt is the sodium salt and has a mean average molecular weight of from about 650,000 to about 800,000, a sulphated ash content below about 15% and a protein content below about 5%.

30 6. The composition of claim 1, wherein the nonionic polymers are selected from the group consisting of carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose and mixtures thereof.

35 7. The composition of claim 1, wherein the nonionic polymer is hydroxyethyl cellulose.

42

8. A stable, sterile composition which comprises: an active drug solubilized within a matrix containing a negative charged polymer having a mean average molecular weight between about 650,000 and 800,000 blended with a nonionic polymer, wherein the molar ratio of the charged polymer to the nonionic polymer is 1:0.5 to 2.

9. The solution of claim 8, wherein the negative charged polymer is a mucopolysaccharide polymer having an average molecular weight between about 700,000 and about 775,000.

10. The solution of claim 9, wherein the charged polymer is the hyaluronate salt of sodium, calcium, potassium or magnesium.

11. The solution of claim 8, wherein the nonionic polymers are selected from the group consisting of carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose and mixtures thereof.

12. The solution of claim 8, wherein the molar ratio of the polymers is 1:0.8 to 1.5.

13. The solution of claim 8, wherein the charged polymer is present in amounts of about 0.1% to about 2.0% by weight.

14. The solution of claim 8, wherein the nonionic polymers are present in amounts of about 0.1% to about 1.0% by weight.

15. A stable, sterile gelled composition which comprises: an active drug dispersed within a matrix containing a negative charged polymer having a mean average molecular weight between about 650,000 and 800,000 blended with a nonionic polymer, wherein the molar ratio of the charged polymer to the nonionic polymer is 1:0.5 to 2 and the negative

43

charged polymer is present in amounts of about 2.0% to about 3.0% by weight.

5 16. The gel of claim 15, wherein the negative charged polymer is a mucopolysaccharide polymer having an average molecular weight between 700,000 to 775,000.

10 17. The gel of claim 16, wherein the charged polymer is the hyaluronate salt of sodium, calcium, potassium or magnesium.

15 18. The gel of claim 15, wherein the nonionic polymers are selected from the group consisting of carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose and mixtures thereof.

19. The gel of claim 15, wherein the molar ratio of the polymers is 1:0.8 to 1.5.

20 20. The gel of claim 15, wherein the charged polymer is present in amounts of about 0.1% to about 2.0% by weight.

25 21. The gel of claim 15, wherein the nonionic polymers are present in amounts of above about 1.0% by weights.

22. A method for the treatment of a condition in animals for a sustained period of time, which comprises:

30 injecting a therapeutically effective dose of a suspension or solution of a sterilized, purified, drug composition comprising a drug dispersed within a polymer matrix which is solubilized or suspended in a liquid medium; wherein the polymer matrix contains a negatively charged polymer blended with a nonionic polymer.

44

23. The method of claim 22, wherein the negatively charged polymer material is selected from the group consisting of glucoaminoglycans, mucopolysaccharides and mixtures thereof.

5

24. The method of claim 22, wherein the negative charged polymer material is hyaluronic acid salt.

10

25. The method of claim 24, wherein the material has a mean average molecular weight below about 800,000.

15

26. The method of claim 24, wherein the hyaluronic acid salt is the sodium salt and has a mean average molecular weight from about 650,000 to about 800,000, a sulphated ash content below about 15%, a protein content below about 5% and purity of at least 98%.

20

27. The method of claim 22, wherein the nonionic polymer is selected from the group consisting of carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose and mixtures thereof.

25

28. The method of claim 22, wherein a therapeutically effective dose is administered to treat acute, chronic or intractable diseases or conditions.

30

29. The method of claim 28, wherein the condition treated is chronic intractable or sympathetically mediated pain.

35

30. The method of claim 22, wherein the therapeutically effective dosage penetrates the lipoprotein nerve sheath to alleviate the pain without significantly modifying motor or sensory functions.

45

31. The method of claim 22, wherein a therapeutically effective dose is administered during or after abdominal, cervical, thoracic or cardiac surgery, to treat postoperative pain and post amputation.

32. The method of claim 22, wherein the pain treated is associated with or caused by abnormal cell growth, cancer, tumor mass, arthritis, sickle cell disease, hemophilia, pinched nerve, damaged nerve, or migraine.

33. The method of claim 22, wherein a therapeutically effective dose is administered to treat the peripheral nerve responsible for carrying the nociception.

34. The method of claim 22, wherein a therapeutically effective dosage is administered epidurally, subcutaneously, epidermally or intramuscularly.

46

-- 35. A sustained release delivery system, which comprises:

a polymer matrix solubilized or suspended in a liquid medium; wherein the polymer matrix is composed of negative charged polymers blended with nonionic polymers.

36. The composition of claim 35, wherein the negative charged polymer material is selected from the group consisting of polysulfated glucosoglycans, glycosamineoglycans, mucopolysaccharides and mixtures thereof.

37. The composition of claim 36, wherein the negative charged polymer material is selected from the group consisting of hyaluronic acid salts, chondroitin sulfate and mixtures thereof.

38. the composition of claim 37, wherein the negative charged polymer material has a mean average molecular weight below about 800,000.

39. The composition of claim 37, wherein the hyaluronic acid salt is the sodium salt and has a mean average molecular weight of from about 650,000 to about 800,000, a sulphated ash content below about 15% and a protein content below about 5%.

40. The composition of claim 35, wherein the nonionic polymers are selected from the group consisting of carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose and mixtures thereof.

47

41. The composition of claim 35, wherein the nonionic polymer is hydroxyethyl cellulose.

42. A sustained release delivery system, which comprises: a polymer matrix suspended or solubilized in a liquid medium, wherein the polymer matrix contains a negative charged polymer having a mean average molecular weight between about 650,000 and 800,000 blended with a nonionic polymer, and wherein the molar ratio of the negative charged polymer to the nonionic polymer is 1:0.5 to 2.

43. The solution of claim 42, wherein the negative charged polymer is a mucopolysaccharide polymer having an average molecular weight between about 700,000 and about 775,000.

44. The solution of claim 43, wherein the charged polymer is the hyaluronate salt of sodium, calcium, potassium or magnesium.

45. The solution of claim 42, wherein the nonionic polymers are selected from the group consisting of carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose and mixtures thereof.

46. The solution of claim 42, wherein the molar ratio of the polymers is 1:0.8 to 1.5.

47. The solution of claim 42, where the negative charged polymer is present in amounts of about 0.1% to about 2.0% by weight.

48

48. The solution of claim 42, wherein the nonionic polymers are present in amounts of about 0.1% to about 1.0% by weight.

49. A method for making a sustained release delivery system which comprises:

combining an aqueous solution of a negative charged polymer with an aqueous solution of a nonionic polymer to form a polymer matrix;

blending the solutions together to form a solution or suspension of the components; and

sterilizing the resulting composition. --

50. The method of claim 49, wherein the negative charged polymer material is selected from the group consisting of polysulfated glucosoglycans, glycosaminoglycans, mucopolysaccharides and mixtures thereof. --

51. The method of claim 49, wherein the negative charged polymer material is selected from the group consisting of hyaluronic acid salts, chondroitin sulfate and mixtures thereof. --

52. The method of claim 49, wherein the negative charged polymer material has a mean average molecular weight below about 800,000. --

53. The method of claim 49, wherein the hyaluronic acid salt is the sodium salt and has a mean average molecular weight of from about 650,000 to about 800,000, a sulphated ash content below about 15% and a protein content below about 5%. --

49

54. The method of claim 49, wherein the nonionic polymers are selected from the group consisting of carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose and mixtures thereof.

55. The method of claim 49, wherein the nonionic polymer is hydroxyethyl cellulose.

56. The method of claim 49, wherein a stable, sterile composition, which comprises: an active drug solubilized within a matrix containing a negative charged polymer having a mean average molecular weight between about 650,000 and 800,000 blended with a nonionic polymer, wherein the molar ratio of the negative charged polymer to the nonionic polymer is 1:0.5 to 2.

57. The method of claim 49, wherein the negative charged polymer is a mucopolysaccharide polymer having an average molecular weight between about 700,000 and about 775,000.

58. The method of claim 49, wherein the charged polymer is the hyaluronate salt of sodium, calcium, potassium or magnesium.

59. The method of claim 49, wherein the nonionic polymers are selected from the group consisting of carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose and mixtures thereof.

60. The method of claim 49, wherein the molar ratio of the polymers is 1:0.8 to 1.5.

50

61. The method of claim 49, wherein the negative charged polymer is present in amounts of about 0.1% to about 2.0% by weight.

62. The method of claim 49, wherein the nonionic polymers are present in amounts of about 0.1% to about 1.0% by weight.

63. The method of claim 49, wherein the negative charged polymer solution is added to the nonionic polymer solution.

64. The method of claim 49, wherein the nonionic polymer solution is added to the negative charged polymer solution.

65. The method of claim 49, wherein the solutions are added together to form a polymer matrix.

51

~~66~~ 1. A long acting analgesic or antagonist drug composition which comprises:

5 a water-soluble analgesic or antagonist drug dispersed within a polymer matrix which is solubilized in an aqueous medium; wherein the polymer matrix is composed of negative charged polymers blended with nonionic polymers.

10 ~~67~~ 2. The composition of claim ~~1~~⁶⁶, wherein the negative charged polymer material is selected from the group consisting of hyaluronic acid salts, chondroitin sulfate and mixtures thereof.

15 ~~68~~ 3. The composition of claim ~~2~~⁶⁷, wherein the negative charged polymer material has a mean average molecular weight below about 800,000.

20 ~~69~~ 4. The composition of claim ~~3~~⁶⁸, wherein the hyaluronic acid salt is the sodium salt and has a mean average molecular weight of from about 650,000 to about 800,000, a sulphated ash content below about 15% and a protein content below about 5%.

25 ~~70~~ 5. The composition of claim ~~4~~⁶⁶, wherein the nonionic polymers are selected from the group consisting of carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose and mixtures thereof.

30 ~~71~~ 6. The composition of claim ~~5~~⁶⁶, wherein the nonionic polymer is hydroxyethyl cellulose.

~~72~~ 7. The composition of claim ~~6~~⁶⁶, wherein the drug is dispersed within the polymer matrix immediately prior to use.

35 ~~73~~ 12. The composition of claim ~~7~~⁷², wherein the drug is a water-soluble solid drug.

52

74 ~~13~~⁷². The composition of claim ~~14~~, wherein the narcotic is previously solubilized in an aqueous medium prior to being disbursed in the polymer matrix.

5 75 ~~14~~. A method for making a long acting analgesic or antagonist injectable drug solution which comprises:

preparing a polymer matrix containing a negative charged polymer having a mean average molecular weight between about 650,000 and 800,000 and a nonionic polymer, wherein the molar
10 ratio of the negative charged polymer to the nonionic polymer is 1:0.5 to 2 and the negative charged polymer is present in amounts of about 0.1% to about 2.0% by weight;

solubilizing within the polymer matrix a water-soluble analgesic or antagonist drug by blending the drug with the
15 polymer matrix solution; and

recovering the resulting solution.

76 ~~15~~⁷⁵. The method of claim ~~14~~, wherein the drug is a water-soluble solid which is mixed into the polymer matrix solution
20 prior to use.

77 ~~16~~⁷⁵. The method of claim ~~14~~, wherein the drug is in the form of a solution prior to mixing with the polymer matrix solution.

25 78 ~~17~~. A method for the treatment of a pain in an animal for a long period of time, which comprises:

intramuscularly injecting a therapeutically effective dose of a solution of a water-soluble analgesic or antagonist drug solubilized within a polymer matrix, wherein the polymer matrix
30 contains a negatively charged polymer and a nonionic polymer in an aqueous solution; and wherein the dosage is effective to provide therapeutically effective levels of the drug for periods of time of at least 18 hours with amounts of drug that would be considered less than therapeutically effective for such time
35 periods.

53

79 ~~18~~. The method of claim ~~17~~⁷⁸, wherein the condition is alleviated without significantly modifying motor or sensory function.

5 80 ~~19~~. The method of claim ~~17~~⁷⁸, wherein the condition is pain associated with a neoplastic or cancerous condition.

81 ~~20~~. The method of claim ~~17~~⁷⁸, wherein the condition is back pain.

10 82 ~~21~~. The method of claim ~~17~~⁷⁸, wherein the condition is associated in a surgical procedure.

15 83 ~~22~~. A method for the treatment of drug addiction in an animal, which comprises:

20 intramuscularly injecting a therapeutically effective dose of a solution of a water-soluble analgesic or antagonist drug composition comprising the drug dispersed within a polymer matrix which is solubilized in an aqueous medium; wherein the polymer matrix contains a negatively charged polymer blended with a nonionic polymer.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/15293

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 9/08
US CL :424/484,488

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/484,488

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,358,973 A (LINDBLAD et al.) 25 October 1994, column 3, lines 13-21 and 36-50.	1-5
Y	US 5,356,629 A (SANDER et al.) 18 October 1994, column 2, lines 35-66, column 3, lines 20-22, 38-47, 51-53 and Examples 9 and 10.	1-28,34-48
Y	US 5,143,724 A (LESHCHINER et al.) 01 September 1992, column 2, lines 59-65, column 3, lines 1-14, 40-44, 59-62, column 4, lines 29-52, column 6, lines 59-64, column 7, lines 60-64, column 9, lines 20-22 and Example 4.	49-77



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

01 JANUARY 1997

Date of mailing of the international search report

21 JAN 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

AMY HULINA

Telephone No. (703) 368-2351